Cardiac Science to Present at Wells Fargo Securities' 2005 Healthcare Conference

Cardiac Science to Present at Wells Fargo Securities' 2005
Healthcare Conference 


IRVINE, Calif., Feb. 24  /PRNewswire-FirstCall/ -- Cardiac Science Inc.
(NASDAQ:DFIB) today announced that Chairman and CEO Raymond W. Cohen is
scheduled to make an investor presentation at Wells Fargo Securities' 2005
Healthcare Conference on Wednesday, March 2, 2005 at 11:15 a.m. Eastern Time.
The conference is being held at the St. Regis Hotel in New York City.

A live webcast of the Company's presentation at the conference will be
available via a link provided at the Company's website at
http://www.cardiacscience.com/.  An archive of the presentation will begin
shortly after the presentation time and will be available for 30 days.

About Cardiac Science

Cardiac Science develops, manufactures and markets a complete line of
Powerheart(R) brand, automated public access defibrillators (AEDs), and offers
comprehensive AED/CPR training and AED program management services that
facilitate successful deployments.  The company makes the Powerheart(R)
CRM(TM), the only FDA-cleared therapeutic patient monitor that instantly and
automatically treats hospitalized cardiac patients who suffer life-threatening
heart rhythms.  Cardiac Science also manufactures its AED products on a private
label basis for other leading medical companies such as Nihon Kohden (Japan),
Quinton Cardiology Systems and GE Healthcare.  For more information please
visit http://www.cardiacscience.com/ or call 1.949.797.3800.

This news release contains "forward-looking statements" within the meaning of
the Private Securities Litigation Reform Act of 1995.  In addition, from time
to time the company, or its representatives, have made or may make forward
looking statements orally or in writing.  The words "estimate," "potential,"
"intended," "expect," "anticipate," "believe," and similar expressions or words
are intended to identify forward looking statements. Such forward-looking
statements include, but are not limited to the achievement of future revenue
growth based on the expanded agreement with GE. Cardiac Science cautions that
these statements are subject to substantial risks and uncertainties and are
qualified by important factors that could cause actual results to differ
materially from those reflected by the forward- looking statements and should
not be relied upon by investors when making an investment decision. 
Information on these and other factors is detailed in the Company's Form 10-K
for the year ending December 31, 2003, subsequent quarterly filings, and other
documents filed by the Company with the Securities and Exchange Commission.

  Contact:  Matt Clawson (Investors)     Michael D. Gioffredi
            Allen & Caron Inc            Chief Marketing Officer
            [phone]               Cardiac Science, Inc.
                      [phone]
                                         

DATASOURCE: Cardiac Science Inc.



CONTACT:  Investors, Matt Clawson of Allen & Caron Inc, [phone],

, for Cardiac Science, Inc.; or  Michael D. Gioffredi,

Chief Marketing Officer of Cardiac Science, Inc., [phone],





Web site:  http://www.cardiacscience.com/ 

Copyright